가바펜틴 400밀리그람 캡슐의 생물학적동등성시험 = Bioequivalence Test of Gabapentin 400 mg Capsules

다국어 초록 (Multilingual Abstract)

Gabapentin, [1-(aminomethyl) cyclohexaneacetic acid], a structural analog of $\gamma$-aminobutyric acid (GABA), is being developed for the treatment of epilepsy. Unlike GABA, gabapentin crosses the blood-brain barrier after systemic administration. Gabapentin is an effective antiepileptic drug in patients with partial and secondarily generalized seizures who are uncontrolled with use of existing anticonvulsant drug therapy. The purpose of the present study was to evaluate the bioequivalence of two gabapentin 400 mg capsules, $Neurontin^{(R)}$ capsule 400 mg (Pfizer Inc.) and Gabatin capsule 400 mg (Korean Drug Co. Ltd), according to the guidelines of the Korea Food and Drug Administration (KFDA). The release of gabapentin from the two gabapentin formulations in vitro was tested using KP VIII Apparatus II method with various dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty six healthy male subjects, 23.58$\pm$1.50 years in age and 66.74$\pm$8.31 kg in body weight, were divided into two groups and a randomized 2$\times$2 cross-over study was employed. After one capsule containing 400 mg as gabapentin were orally administered, blood was taken at predetermined time intervals and the concentrations of gabapentin in serum were determined using HPLC with fluorescence detector. The dissolution profiles of two formulations were similar at all dissolution media. In addition, the pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, $Neurontin^{(R)}$ capsule 400 mg, were 2.04, -3.68 and 16.79% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., log 0.91$\sim$log 1.16 and log 0.87$\sim$log 1.11 for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Gabatin capsule 400 mg was bioequivalent to $Neurontin^{(R)}$ capsule 400 mg.

참고문헌 (Reference)

1 식품의약품안전청, "식품의약품안전청 고시 제2005-31호, 생물학적동등성시험기준"

2 식품의약품안전청, "식품의약품안전청 고시 제1999-67호, 의약품임상시험관리기준"

3 조혜영, "뉴론틴 캡슐 300밀리그람(가바펜틴 300�mg)에 대한 건일가바펜틴 캡슐300밀리그람의 생물학적동등성" 한국약제학회 35 (35): 193-199, 2005

4 "Statistical Solutions Ltd., Equiv Test® 2.0, U.K"

5 Wad, N., "Sensitive high-performance liquid chromatographic method with fluorometric detection for the simultaneous determination of gabapentin and vigabatrin in serum and urine" 705 (705): 154-, 1998

6 Blum, R. A., "Pharmacokinetics of gabapentin in subjects with various degrees of renal function" 56 (56): 154-, 1994

7 Rowbotham, M., "Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial" 280 : 1837-, 1998

8 Forrest, G., "Determination of gabapentin in plasma by high-performance liquid chromatography" 681 (681): 421-, 1996

9 Elwes, R. D. C., "Clinical pharmacokinetics of newer antiepileptic drugs" 30 (30): 403-, 1996

10 Tang, P. H., "Automated microanalysis of gabapentin in human serum by high-performance liquid chromatography with fluorometric detection" 727 : 125-, 1999